OUR

LEADERSHIP

TEAM

Verity Pharmaceuticals has a highly qualified, dedicated, and experienced team with decades of global experience in the development and commercialization of prescription therapeutics.

Verity Pharmaceuticals is supported by globally-recognized scientific, clinical, and healthcare thought leaders, business strategists, and investment advisors.


Howard M. Glase
HOWARD M. GLASE
CEO and General Manager

Howard brings over 25 years of Canadian and U.S. corporate pharmaceutical senior commercial management experience to Verity Pharmaceuticals. Howard has also gained experience as a CEO within the medical market research, scientific communications, and medical education industries.

Howard brings over 25 years of Canadian and U.S. corporate pharmaceutical senior commercial management experience to Verity Pharmaceuticals. Howard has also gained experience as a CEO within the medical market research, scientific communications, and medical education industries.

Acquired corporate pharmaceutical brand experiences include the launch of Cipro in Canada and Cipro IV for global markets. Additionally, Howard launched Cardizem CD in Canada and moved to the national commercial team in the U.S. (Sanofi) on the cardiovascular portfolio, with national responsibilities on Cardizem CD ($1.3 billion in sales) and led the launch of Teczem (co-promoted with Merck) in the American cardiovascular market.

For the past 15 years, Howard has focused his entrepreneurial passion on developing healthcare businesses in the biotech and pharmaceutical industries. The successful entrepreneurial ventures included a scientific publishing business and a primary health science market research company. Howard has also been involved in providing healthcare consultation services to Canadian, American, and Internationally based pharmaceutical companies.

Howard studied at the University of Ottawa in Kinesiology and Health Sciences, completed a corporate-sponsored MBA certificate program in finance at Princeton University, NJ, and an executive MBA diploma course in International Business at the University of Western Ontario, London, Ontario.

Scott Doherty
SCOTT DOHERTY, CPA
Chief Financial Officer

Scott’s background includes strategic pharmaceutical planning, financial analytics, consulting, business development, and tax planning within a multinational pharmaceutical organization. He achieved extensive executive decision-making accomplishments at Allergan Canada as the Senior Finance Manager, supporting senior management.

Scott’s background includes strategic pharmaceutical planning, financial analytics, consulting, business development, and tax planning within a multinational pharmaceutical organization. He achieved extensive executive decision-making accomplishments at Allergan Canada as the Senior Finance Manager, supporting senior management.

During this time, Scott was responsible for overseeing the primary and specialty care business unit. Soon after, he was promoted to lead commercial analytics and planning within operations. There, his responsibilities included designing and implementing sales force compensation packages, business intelligence software, analytics, and forecasting, as well as assessing ROI, resource sizing, and allocation.

A CPA, Scott began his career in public accounting before becoming a senior financial analyst at a multinational traded company.

As the Verity CFO, Scott works within the Executive Team to contribute to the financial planning and governance of the company’s growth plans.

Jay Silber
JAY SILBER, LLB
Chief Operating Officer and General Counsel

Jay joined Verity in 2019 as Chief Operating Officer and General Counsel and brings with him more than 13 years of experience working with numerous multinational clients providing guidance within business governance and legal initiatives.

Jay joined Verity in 2019 as Chief Operating Officer and General Counsel and brings with him more than 13 years of experience working with numerous multinational clients providing guidance within business governance and legal initiatives.

During his career, he has undertaken numerous clients, managing complex business and negotiation positions within the Canadian market. Jay is recognized for his deep ethical sense, respect of others, and talent for developing long-term business relationships.

Jay holds a Bachelor of Laws degree from the University of Windsor and a Bachelor of Arts from Concordia University. When not in the office, Jay is involved in a number of philanthropic initiatives, is an avid reader, and spends time with his wife and three daughters.

Dr. Neil Fleshner
DR. NEIL FLESHNER, MD, MPH, FRCSC
Chief Medical Officer

Dr. Neil Fleshner graduated with a medical degree from the University of Toronto in 1988. He completed specialty training in urologic surgery and oncology from 1993 to 1996, received a Master’s in Public Health in epidemiology from Columbia University in 1997, and completed his oncology training at Memorial Sloan-Kettering Cancer Center. Dr. Fleshner is certified in both urology and epidemiology.

Dr. Neil Fleshner graduated with a medical degree from the University of Toronto in 1988. He completed specialty training in urologic surgery and oncology from 1993 to 1996, received a Master’s in Public Health in epidemiology from Columbia University in 1997, and completed his oncology training at Memorial Sloan-Kettering Cancer Center. Dr. Fleshner is certified in both urology and epidemiology.

Dr. Fleshner is the Martin Barkin Professor and Chairman of Urology at the University of Toronto and has been a urology fellow of the Royal College of Physicians and Surgeons of Canada for more than 25 years. Dr. Fleshner is also a Professor of Surgery at the University of Toronto.  In the past, he has served as the Head of the Division of Urology at the University Health Network, and the Head of Genitourinary Cancer Site group at the Princess Margaret Hospital. He also holds the prestigious Love Chair in prostate cancer prevention at Princess Margaret Hospital.

Aside from surgical practice, Dr. Fleshner is the lead or co-investigator on numerous studies researching urologic cancer prevention with an emphasis on prostate cancer. His current projects include two randomized trials of intervention in prostate cancer, as well as laboratory work assessing prostate cancer metabolism. Dr. Fleshner has had a prolific research career, authoring over 400 scientific papers, books, and book chapters on prostate disease. Dr. Fleshner is a highly sought-after speaker, having delivered many talks and poster presentations all over the world over the last 25 years.

Tyler Cowan
TYLER COWAN
Vice President, Business Development

Tyler brings over 18 years of healthcare experience in marketing, sales, sales leadership, and corporate/government affairs including more than 10 years designing innovative multi-platform commercial and patient support solutions.

Tyler brings over 18 years of healthcare experience in marketing, sales, sales leadership, and corporate/government affairs including more than 10 years designing innovative multi-platform commercial and patient support solutions.

Tyler’s experience includes managing contract negotiations as well as design and deployment of complex contract and partnership agreements with organizations ranging from start-up biopharma to large Top 10 pharmaceutical companies.

Taniya Mann
TANIYA MANN, PhD, MBA
Vice President and Head of Scientific Affairs, Canada

Taniya has more than 20 years of experience in the pharmaceutical and consumer products industries with multi-national companies, covering all areas of drugs, devices, NHPs, and cosmetics.

While currently responsible for managing the Canadian business, Taniya is also responsible for all Regulatory, Quality and Pharmacovigilance activities.

Taniya has more than 20 years of experience in the pharmaceutical and consumer products industries with multi-national companies, covering all areas of drugs, devices, NHPs, and cosmetics.

While currently responsible for managing the Canadian business, Taniya is also responsible for all Regulatory, Quality, and Pharmacovigilance activities.

Taniya obtained her Hons. BSc in Molecular Genetics and Molecular Biology from the University of Toronto, followed by a PhD in Neuropharmacology from the University of Nottingham and an MBA from Boston College.

Taniya then began pursuing her career in regulatory affairs. Her corporate background includes companies such as AstraZeneca, Boehringer Ingelheim, Apotex, and Reckitt Benckiser.

She has led numerous successful filings, including NHPs, OTCs, Cosmetics, Disinfectants, Devices, and Rx Drugs. The marketing authorizations obtained have been in a number of therapeutic areas including gastrointestinal, cardiovascular, respiratory, and oncology, and have included biologics and generics.

Robert Murphy
ROBERT MURPHY
Vice President, Sales and Market Access

Robert joined Verity in 2021 as Vice President and brings more than 25 years of experience in the pharmaceutical industry. He has been instrumental in the U.S. commercial strategy and team expansion and has been involved with numerous aspects of the business.

Robert joined Verity in 2021 as Vice President and brings more than 25 years of experience in the pharmaceutical industry. He has been instrumental in the U.S. commercial strategy and team expansion and has been involved with numerous aspects of the business.

Robert joins Verity with a long history in the pharmaceutical industry touching multiple functional areas, including market access, sales and marketing, and business development. His drive and entrepreneurial spirit embody the core principals here at Verity Pharmaceuticals.

Robert’s primary responsibilities include leading the U.S. Sales and Market Access efforts and supporting portfolio development in both the U.S. and Puerto Rico.

Wayne Caldwell
WAYNE CALDWELL
Head of U.S. Commercial Operations

Wayne brings over 25 years of broad-based healthcare experience spanning sales, marketing, data analytics, and commercial effectiveness to Verity Pharmaceuticals.

Wayne brings over 25 years of broad-based healthcare experience spanning sales, marketing, data analytics, and commercial effectiveness to Verity Pharmaceuticals.

Wayne began his pharmaceutical career with Bayer Canada, then moved on to Pfizer in sales and product management roles prior to joining Bristol Myers-Squibb where he held a variety of marketing and corporate development positions in Canada and the U.S. For the past decade Wayne has held senior roles in business development and strategic consulting, advising to a host of start-up through large multinational pharmaceutical organizations.

Wayne holds a BEd – Science degree from the University of New Brunswick Canada and undertook graduate studies in science at York University, Toronto, Canada.